Pricing

TRANZYME INC

0 followers ·
DURHAM NC
Tranzyme is based out of Durham. Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal (GI) motility disorders. GI motility disorders are conditions which disrupt the normal movement of food throughout the GI tract. Tranzyme��������s two most advanced product candidates, ulimorelin, which is in Phase 3, and TZP-102, which is entering Phase 2b, are being evaluated for the treatment of predominantly upper GI motility disorders. Approximately 20 percent of adults worldwide are affected by conditions these product candidates are designed to treat. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. In addition to ulimorelin and TZP-102, Tranzyme is also developing a motilin antagonist, TZP-201, for the treatment of various forms of moderate-to-severe diarrhea, and a ghrelin antagonist, TZP-301, for the treatment of obesity and other metabolic diseases.Whalewisdom has at least 155 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2013-11-21. The notice included securities offered of Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Contact Info

Contact information is taken directly from publicly disclosed SEC filings.

TRANZYME INC
4819 EMPEROR BOULEVARD, SUITE 400
DURHAM NC    27703

Business Phone: 919 313-4760
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Recent SEC Filings

Filing Date
SC 13G/A 2018-02-14
SC 13G/A 2018-02-14
UPLOAD 2017-11-14
15-12B 2017-12-21
SC 13D/A 2017-12-21
SC 13D/A 2017-12-14
EFFECT 2017-12-13
EFFECT 2017-12-13
EFFECT 2017-12-13
4 2017-12-13